Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (QNRX) reports news about a late clinical-stage specialty pharmaceutical company developing therapies for rare and orphan diseases. Updates center on QRX003 lotion for Netherton Syndrome and related rare skin disorders, including clinical-study progress and U.S. and European orphan, rare pediatric disease and fast track regulatory designations.
Company news also covers QRX009 topical rapamycin development programs, rare dermatologic and genetic disease research, quarterly financial results, private-placement financing and distribution or commercialization arrangements for potential international markets.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced the dosing of the first patient in its open-label clinical trial for QRX003 targeting Netherton Syndrome. This study evaluates the safety and efficacy of QRX003 in patients receiving off-label systemic therapy over a twelve-week period. Various clinical endpoints will be assessed, including Investigator Global Assessment and Patient Global Assessment. Concurrently, Quoin is also running a double-blind vehicle-controlled study for QRX003. The company expects to report topline data from this trial in the latter half of 2023. These efforts position QRX003 as a potential standard of care for Netherton patients.